Companies › Alasht Pharmed
1 active drug program in 1 registered trial: 1 Phase 4; Neurology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Canvert-M Topical cannabidiol with essential oils (peppermint, lavender, rosemary, eucalyptus, winte | CNR1, CNR2 | Phase 4 | Migraine Disorders | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07093138 | Canvert-M | Phase 4 | Migraine Disorders | Neurology | Sep 2025 |
IGC Pharma Zynerba Pharmaceuticals Bazelet Nehushtan Incannex Healthcare Vertanical Jazz Pharmaceuticals Sinfatin Skye Bioscience PleoPharma Laboratorio Elea Phoenix
Sound Wave Innovation NeuroTherapia Navamedic Danyang Huichuang Medical Equipment Dyne Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.